Effect of HPV on head and neck cancer patient survival, by region and tumor site: A comparison of 1362 cases across three continents

D'Souza, G. et al. (2016) Effect of HPV on head and neck cancer patient survival, by region and tumor site: A comparison of 1362 cases across three continents. Oral Oncology, 62, pp. 20-27. (doi: 10.1016/j.oraloncology.2016.09.005) (PMID:27865368)

132201.pdf - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.



Objectives: To explore whether HPV-related biomarkers predict oropharyngeal squamous cell cancer (OPSCC) survival similarly across different global regions, and to explore their prognostic utility among non-oropharyngeal (non-OP) head and neck cancers. Methods: Data from 1362 head and neck SCC (HNSCC) diagnosed 2002–2011 was used from epidemiologic studies in: Brazil (GENCAPO study, n = 388), U.S. (CHANCE study, n = 472), and Europe (ARCAGE study, n = 502). Tumors were centrally tested for p16INK4a and HPV16 DNA (by PCR). Risk of mortality was examined using Cox proportional hazard models. Results: There were 517 OPSCC and 845 non-OP HNSCC. Cases were primarily male (81%), ever smokers (91%), with median age of 58 years and median follow-up of 3.1 years (IQR = 1.4–5.9). Among OPSCC, the risk of mortality was significantly lower among 184 HPV-related (i.e., p16+/HPV16+) compared to 333 HPV-unrelated (p16- and/or HPV16-) cases (HR = 0.25, 95%CI = 0.18–0.34). Mortality was reduced among HPV-related OPSCC cases from the U.S., Europe, and Brazil (each p ⩽ 0.01) and after adjustment, remained significantly reduced (aHR = 0.34, 95%CI = 0.24–0.49). Among non-OP HNSCC, neither p16 (aHR = 0.83, 95%CI = 0.60–1.14), HPV16 DNA (aHR = 1.20, 95%CI = 0.89–1.63), or p16+/HPV16+ (aHR = 0.59, 95%CI = 0.32–1.08) was a significantly predictor of mortality. When interaction was tested, the effect of HPV16/p16 was significantly different in OPSCC than non-OP HNSCC (p-interaction = 0.02). Conclusion: HPV-related OPSCCs had similar survival benefits across these three regions. Prognostic utility of HPV among non-OP HNSCC is limited so tumor HPV/p16 testing should not be routinely done among non-OP HNSCC.

Item Type:Articles
Additional Information:A correction to this article is available at http://dx.doi.org/10.1016/j.oraloncology.2016.12.023.
Glasgow Author(s) Enlighten ID:Conway, Professor David
Authors: D'Souza, G., Anantharaman, D., Gheit, T., Abedi-Ardekani, B., Beachler, D. C., Conway, D. I., Olshan, A. F., Wunsch-Filho, V., Toporcov, T. N., Ahrens, W., Wisniewski, K., Merletti, F., Boccia, S., Tajara, E. H., Zevallos, J. P., Levi, J. E., Weissler, M. C., Wright, S., Scelo, G., Mazul, A. L., Tommasino, M., Brennan, P., and Cadoni, G.
College/School:College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing > Dental School
Journal Name:Oral Oncology
Published Online:26 September 2016
Copyright Holders:Copyright © 2016 Elsevier Ltd.
First Published:First published in Oral Oncology 62: 20-27
Publisher Policy:Reproduced in accordance with the publisher copyright policy
Related URLs:

University Staff: Request a correction | Enlighten Editors: Update this record